Johannes Gutenberg University Mainz — Clinical Trial Site

19 Registered trials

10 Currently recruiting

Organisation

Johannes Gutenberg University Mainz

Location

Mainz, Germany

Identifier

ORG-100022224

Address

Langenbeckstrasse 1, 55101, Germany

Departments

#4910: Dermatology
1. Medizinische Klinik und Poliklinik Hepatologie
Allgemein-, Visceral- und Transplantationschirurgie
Cardiac and vascular surgery
Clinic and Polyclinic for Paediatrics I
Dermatology
Hautklinik
HNO
III Med. Hämatologie/Onkologie
III. Medizinische Klinik und Poliklinik
Internal Medicine
Klinik für Innere Medizin
Klinik und Poliklinik für Radioonkologie und Strahlentherapie
Pädiatrische Hämatologie und Onkologie
Rheumatology
Studienzentrum der Klinik und Poliklinik für Neurologie
Zentrum für Kardiologie
Zentrum für Kinder- und Jugendmedizin

Clinical trials at this site (19)

Search interface

A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k… Not authorised

2022-501389-23-00 end-stage renal disease or otherwise an insufficient ki 4
A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k… Pending

2022-501389-23-02 end-stage renal disease or otherwise an insufficient ki 4
Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC Pending

2024-517937-41-00 extensive stage small cell lung cancer (SCLC) 4
A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High R… Recruiting

2025-523037-25-00 Patients at high risk for Cardiac Surgery Associated – 4 2026-03-10
SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting

2025-520794-39-00 Arterial Hypertension 5 2025-12-10
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2023-09-26
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
A Study to Compare Vusolimogene oderparepvec (VO) Plus Nivolumab With the Doctor's Choice of Treatment in People With Skin Cancer That has G… Recruiting

2023-508612-29-00 Advanced Melanoma 5 2025-11-07
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting

2023-505232-36-00 Essential thrombocythemia 5 2024-11-15
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Primary diffuse large B-cell lymphoma of the central ne 5 2023-08-09
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Ewing Sarcoma 5 2022-06-17
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica… Recruiting

2022-501454-11-00 standard risk ALK-positive anaplastic large cell lympho 5 2020-02-05
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Prurigo nodularis 4 2024-09-25
Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC… Ended

2023-508635-31-00 Hepatocellular Carcinoma 5 2019-12-03
Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended

2023-505376-30-00 BRAF V600 mutation–positive unresectable or metastatic 4 2018-10-30
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Lymphoma of B-cell origin 7 2018-05-16
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended

2024-513658-31-00 Idiopathic Sudden Sensorineural Hearing Loss 4 2022-08-08
A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SPIRONOLACTONE FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTH… Ended

2024-516884-10-00 RHEUMATOID ARTHRITIS 5 2022-06-22